By Aphios Corp.
CXF fractionation technology is utilized to effectively disrupt marine microorganisms and selectively extract bioactive compounds based on their polarities. In comparative screening programs with Bristol-Myers Squibb and Pfizer, CXF technology was shown to: - Produce a unique spectrum of secondary metabolites - Reduce interference from nuisance compounds - Minimize background noise in sensitive molecular assays - Enhance the probability of “clean” hits A closely related CXP technology platform can be utilized to manufacture drugs for preclinical development and commercial production.
